289 related articles for article (PubMed ID: 11109640)
41. Cost-effectiveness of vaccinating adults with the 23-valent pneumococcal polysaccharide vaccine (PPV23) in Germany.
Jiang Y; Gauthier A; Annemans L; van der Linden M; Nicolas-Spony L; Bresse X
Expert Rev Pharmacoecon Outcomes Res; 2012 Oct; 12(5):645-60. PubMed ID: 23025422
[TBL] [Abstract][Full Text] [Related]
42. Cost-effectiveness of pneumococcal conjugate vaccination in Georgia.
Komakhidze T; Hoestlandt C; Dolakidze T; Shakhnazarova M; Chlikadze R; Kopaleishvili N; Goginashvili K; Kherkheulidze M; Clark AD; Blau J
Vaccine; 2015 May; 33 Suppl 1():A219-26. PubMed ID: 25919165
[TBL] [Abstract][Full Text] [Related]
43. Results of a cohort model analysis of the cost-effectiveness of routine immunization with 13-valent pneumococcal conjugate vaccine of those aged > or =65 years in the Netherlands.
Rozenbaum MH; Hak E; van der Werf TS; Postma MJ
Clin Ther; 2010 Aug; 32(8):1517-32. PubMed ID: 20728764
[TBL] [Abstract][Full Text] [Related]
44. Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands.
Mangen MJ; Rozenbaum MH; Huijts SM; van Werkhoven CH; Postma DF; Atwood M; van Deursen AM; van der Ende A; Grobbee DE; Sanders EA; Sato R; Verheij TJ; Vissink CE; Bonten MJ; de Wit GA
Eur Respir J; 2015 Nov; 46(5):1407-16. PubMed ID: 26160871
[TBL] [Abstract][Full Text] [Related]
45. Pneumococcal vaccination in the prevention of community-acquired pneumonia: an optimistic view of cost-effectiveness.
Fedson DS
Semin Respir Infect; 1993 Dec; 8(4):285-93. PubMed ID: 7938925
[TBL] [Abstract][Full Text] [Related]
46. [The cost-effectiveness of pneumococcal vaccination in Catalonia].
Plans Rubió P; Garrido Morales P; Salleras Sanmartí L
Rev Esp Salud Publica; 1995; 69(5):409-17. PubMed ID: 8564860
[TBL] [Abstract][Full Text] [Related]
47. Cost-Effectiveness of Vaccinating Immunocompetent ≥65 Year Olds with the 13-Valent Pneumococcal Conjugate Vaccine in England.
van Hoek AJ; Miller E
PLoS One; 2016; 11(2):e0149540. PubMed ID: 26914907
[TBL] [Abstract][Full Text] [Related]
48. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine in Switzerland.
Blank PR; Szucs TD
Vaccine; 2012 Jun; 30(28):4267-75. PubMed ID: 22521287
[TBL] [Abstract][Full Text] [Related]
49. The impact and cost-effectiveness of pneumococcal immunisation strategies for the elderly in England.
Danelian G; Burton L; Bayley T; Sanchez-Marroquin A; Park J; Manley H; Choi Y; Andrews N; Ladhani S; Earnshaw A; Gritzfeld JF; Trotter C; Panovska-Griffiths J
Vaccine; 2024 Jul; 42(18):3838-3850. PubMed ID: 38763851
[TBL] [Abstract][Full Text] [Related]
50. Cost-effectiveness of the introduction of the pneumococcal polysaccharide vaccine in elderly Colombian population.
Castañeda-Orjuela C; Alvis-Guzmán N; Paternina AJ; De la Hoz-Restrepo F
Vaccine; 2011 Oct; 29(44):7644-50. PubMed ID: 21854825
[TBL] [Abstract][Full Text] [Related]
51. Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race.
Sisk JE; Whang W; Butler JC; Sneller VP; Whitney CG
Ann Intern Med; 2003 Jun; 138(12):960-8. PubMed ID: 12809452
[TBL] [Abstract][Full Text] [Related]
52. Cost-effectiveness analysis of influenza and pneumococcal vaccination for Hong Kong elderly in long-term care facilities.
You JH; Wong WC; Ip M; Lee NL; Ho SC
J Epidemiol Community Health; 2009 Nov; 63(11):906-11. PubMed ID: 19608558
[TBL] [Abstract][Full Text] [Related]
53. Enhanced decision support for policy makers using a web interface to health-economic models--illustrated with a cost-effectiveness analysis of nation-wide infant vaccination with the 7-valent pneumococcal conjugate vaccine in the Netherlands.
Hubben GA; Bos JM; Glynn DM; van der Ende A; van Alphen L; Postma MJ
Vaccine; 2007 May; 25(18):3669-78. PubMed ID: 17360082
[TBL] [Abstract][Full Text] [Related]
54. The cost-effectiveness of pneumococcal vaccination in healthy adults over 50: An exploration of influential factors for Belgium.
Blommaert A; Bilcke J; Willem L; Verhaegen J; Goossens H; Beutels P
Vaccine; 2016 Apr; 34(18):2106-12. PubMed ID: 26988257
[TBL] [Abstract][Full Text] [Related]
55. Cost-effectiveness of a 23-valent pneumococcal polysaccharide vaccine immunization programme for the elderly in Shanghai, China.
Zhao D; Gai Tobe R; Cui M; He J; Wu B
Vaccine; 2016 Dec; 34(50):6158-6165. PubMed ID: 27838068
[TBL] [Abstract][Full Text] [Related]
56. Cost-effectiveness of new adult pneumococcal vaccination strategies in Italy.
Boccalini S; Bechini A; Levi M; Tiscione E; Gasparini R; Bonanni P
Hum Vaccin Immunother; 2013 Mar; 9(3):699-706. PubMed ID: 23295824
[TBL] [Abstract][Full Text] [Related]
57. Economic and clinical evaluation of a catch-up dose of 13-valent pneumococcal conjugate vaccine in children already immunized with three doses of the 7-valent vaccine in Italy.
Boccalini S; Azzari C; Resti M; Valleriani C; Cortimiglia M; Tiscione E; Bechini A; Bonanni P
Vaccine; 2011 Nov; 29(51):9521-8. PubMed ID: 22008820
[TBL] [Abstract][Full Text] [Related]
58. Estimating the cost-effectiveness of a sequential pneumococcal vaccination program for adults in Germany.
Kuchenbecker U; Chase D; Reichert A; Schiffner-Rohe J; Atwood M
PLoS One; 2018; 13(5):e0197905. PubMed ID: 29795647
[TBL] [Abstract][Full Text] [Related]
59. The impact of indirect (herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine.
Isaacman DJ; Strutton DR; Kalpas EA; Horowicz-Mehler N; Stern LS; Casciano R; Ciuryla V
Clin Ther; 2008 Feb; 30(2):341-57. PubMed ID: 18343273
[TBL] [Abstract][Full Text] [Related]
60. Cost Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccination Program in Chronic Obstructive Pulmonary Disease Patients Aged 50+ Years in Spain.
Rodríguez González-Moro JM; Menéndez R; Campins M; Lwoff N; Oyagüez I; Echave M; Rejas J; Antoñanzas F
Clin Drug Investig; 2016 Jan; 36(1):41-53. PubMed ID: 26547199
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
